This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Edward A. Mortimer, Jr, MD

JAMA. 1988;260(10):1454-1455.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

This issue of JAMA contains reports of three retrospective studies^1-3 of the efficacy of Haemophilus b polysaccharide vaccine. The point estimates of protection against invasive disease due to Haemophilus influenzae type b (Hib) are disparate: results of two of these studies^1,2 indicate efficacy (88% and 45%, respectively), but the third study³ found an enhanced risk of invasive Hib disease in vaccinated children ( - 55% efficacy). An explanation for these differing results is not available.

Haemophilus b polysaccharide vaccine, first licensed in the United States in 1985, comprises the capsular polysaccharide from Hib, natural antibodies to which correlate well with clinical immunity to invasive Hib disease. The vaccine's efficacy was shown to be 90% in Finnish children⁴ and the demonstration of antibody production in US children was considered to be a surrogate for clinical protection.⁵ However, in common with other polysaccharide vaccines, efficacy was neither shown nor . . . [Full Text PDF of this Article]

Author Affiliations
Case Western Reserve University School of Medicine Cleveland

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?